BioCardia, Inc. (BCDA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioCardia, Inc. (BCDA) trades at $1.18 with AI Score 27/100 (Grade F). BioCardia, Inc. is a clinical-stage biotechnology company focused on regenerative medicine, particularly in developing advanced cellular therapies for cardiac and respiratory conditions. Market cap: $6.84M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for BCDA: BCDA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BCDA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BCDA: 1/1 perspectives are bearish.
How is this calculated? →BioCardia, Inc. (BCDA) Healthcare & Pipeline Overview
BioCardia, Inc. is a clinical-stage biotechnology firm specializing in regenerative medicine, with a focus on innovative cellular therapies for cardiac and respiratory diseases, particularly through its CardiAMP Cell Therapy System and advanced delivery technologies.
What Is the Investment Thesis for BCDA?
BioCardia, Inc. represents a unique opportunity in the biotechnology sector, driven by its innovative CardiAMP Cell Therapy System, which has shown promising clinical trial data for heart failure and chronic myocardial ischemia. The company's focus on regenerative medicine positions it well within a growing market projected to reach $20 billion by 2028. Key value drivers include the ongoing Phase I/II trials for its allogeneic cell therapy program, which could expand its product offerings and market reach. The successful execution of these trials and subsequent regulatory approvals could lead to significant revenue growth. However, investors should be aware of inherent risks associated with clinical-stage companies, including potential regulatory hurdles and the need for further financing to support ongoing research and development. Monitoring upcoming clinical trial results and regulatory milestones will be crucial for assessing the company's future performance.
Based on FMP financials and quantitative analysis
BCDA Key Highlights
- Market Cap of $6.84M indicates a small-cap status with potential for growth.
- Beta of 0.50 suggests lower volatility compared to the broader market.
- No dividend yield as the company reinvests earnings into R&D.
- Focus on advanced cellular therapies aligns with increasing demand in regenerative medicine.
- Strong pipeline with CardiAMP Cell Therapy System and allogeneic cell therapy program.
Who Are BCDA's Competitors?
BCDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AAPL Apple Inc. | $312.66 | +1.31% | 4593B | 87 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABCL AbCellera Biologics Inc. | $7.87 | -2.96% | $2.40B | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BCDA's Key Strengths?
- Innovative product pipeline with the CardiAMP Cell Therapy System.
- Strong focus on regenerative medicine, addressing unmet medical needs.
- Experienced leadership team with expertise in biotechnology.
What Are BCDA's Weaknesses?
- Limited financial resources due to the clinical-stage status.
- Small workforce may limit operational capacity and scalability.
- Dependence on successful clinical trial outcomes for growth.
What Could Drive BCDA Stock Higher?
- Results from ongoing Phase I/II trials for the allogeneic cell therapy program could provide insights into efficacy and safety.
- Development of the CardiAMP Cell Therapy System continues to progress, with clinical trials expected to yield data in the near term.
- Potential partnerships with healthcare providers could enhance BioCardia's market presence and accelerate product development.
What Are the Key Risks for BCDA?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory approval processes may pose challenges and delays for product launches.
- The need for additional financing could impact operational capabilities and growth initiatives.
- Competition from established biotechnology firms may affect market share and pricing strategies.
What Are the Growth Opportunities for BCDA?
- Growth opportunity 1: The global regenerative medicine market is expected to reach $20 billion by 2028, driven by increasing investments in research and development. BioCardia's focus on innovative therapies for cardiac and respiratory conditions positions it to capture a significant share of this growing market. The ongoing clinical trials for the CardiAMP Cell Therapy System could lead to market entry and revenue generation within the next 2-3 years, depending on regulatory approvals.
- Growth opportunity 2: BioCardia's allogeneic cell therapy program is currently in Phase I/II trials, targeting ischemic systolic heart failure. If successful, this program could provide a new revenue stream and enhance the company's product portfolio. The increasing prevalence of heart failure, projected to affect over 8 million individuals in the U.S. by 2030, presents a substantial market opportunity for BioCardia's therapies.
- Growth opportunity 3: The Helix biotherapeutic delivery system represents a significant innovation in the delivery of cell therapies. By enabling precise administration of treatments directly into the heart muscle, this technology could improve patient outcomes and increase the efficacy of BioCardia's therapies. As the demand for effective delivery systems grows, BioCardia's proprietary technology could become a competitive advantage in the market.
- Growth opportunity 4: Partnerships with healthcare providers and research institutions could enhance BioCardia's clinical trial capabilities and expand its reach in the regenerative medicine space. Collaborations could lead to accelerated development timelines and increased visibility within the industry, fostering growth opportunities.
- Growth opportunity 5: The increasing focus on personalized medicine and tailored therapies aligns with BioCardia's approach of using patient-derived cells for treatment. As healthcare shifts towards more individualized treatment plans, BioCardia's innovative therapies could meet the evolving needs of patients and healthcare providers.
What Opportunities Does BCDA Have?
- Expanding regenerative medicine market offers significant growth potential.
- Ongoing clinical trials could lead to new revenue streams.
- Partnerships with healthcare providers may enhance market reach.
What Threats Does BCDA Face?
- Regulatory hurdles could delay product approvals and market entry.
- Intense competition in the biotechnology sector may impact market share.
- Funding challenges may hinder research and development efforts.
What Are BCDA's Competitive Advantages?
- Proprietary technology for the CardiAMP Cell Therapy System differentiates BioCardia from competitors.
- Innovative delivery systems enhance treatment efficacy and patient outcomes.
- Strong focus on clinical trials and research positions the company as a leader in regenerative medicine.
- Expertise in cellular therapies provides a competitive edge in a rapidly evolving market.
What Does BCDA Do?
Founded with a vision to transform the treatment landscape for cardiac and respiratory ailments, BioCardia, Inc. is a pioneering clinical-stage biotechnology company headquartered in Sunnyvale, California. The company's primary focus is on regenerative medicine, specifically the development of advanced cellular and cell-derived therapies. Central to its pipeline is the CardiAMP Cell Therapy System, which is designed to address significant medical challenges such as heart failure and chronic myocardial ischemia. This innovative system utilizes a patient’s own cells to promote healing and regeneration of damaged heart tissue. In addition to the CardiAMP system, BioCardia is advancing an allogeneic cell therapy program targeting both cardiac and pulmonary conditions. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. The company is also exploring a specific allogeneic cell therapeutic platform that could further enhance its treatment offerings. Beyond its therapeutic candidates, BioCardia provides innovative delivery solutions, including the Helix biotherapeutic delivery system, which is engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle. The company also offers a line of Morph deflectable guides and sheaths, facilitating enhanced delivery of its therapies. With a dedicated team of 17 employees, BioCardia is positioned to make significant strides in the regenerative medicine space, aiming to improve patient outcomes in cardiac and respiratory health.
What Products and Services Does BCDA Offer?
- Develop advanced cellular and cell-derived therapies for cardiac and respiratory ailments.
- Focus on the CardiAMP Cell Therapy System for heart failure and chronic myocardial ischemia.
- Advance an allogeneic cell therapy program targeting cardiac and pulmonary conditions.
- Conduct Phase I/II clinical trials for investigational treatments.
- Provide innovative delivery solutions, including the Helix biotherapeutic delivery system.
- Offer Morph deflectable guides and sheaths for enhanced treatment delivery.
How Does BCDA Make Money?
- Generate revenue through the development and commercialization of innovative therapies.
- Engage in partnerships and collaborations with healthcare providers and research institutions.
- Focus on securing funding through grants and investments to support R&D efforts.
- Monetize proprietary delivery technologies and systems in conjunction with therapies.
What Industry Does BCDA Operate In?
The biotechnology industry is rapidly evolving, with a strong emphasis on regenerative medicine and cell-based therapies. The global regenerative medicine market is projected to grow significantly, driven by advancements in cell therapy, gene therapy, and tissue engineering. BioCardia, Inc. is strategically positioned within this landscape, focusing on innovative treatments for cardiac and respiratory diseases. The competitive landscape includes several players in the regenerative medicine space, but BioCardia's unique approach with the CardiAMP Cell Therapy System and its proprietary delivery technologies differentiate it from others. As the demand for effective treatments for chronic conditions increases, BioCardia's focus on these therapeutic areas aligns well with market trends.
Who Are BCDA's Key Customers?
- Healthcare providers seeking advanced treatment options for cardiac and respiratory conditions.
- Patients suffering from heart failure and chronic myocardial ischemia.
- Research institutions interested in regenerative medicine and cell therapy advancements.
- Investors looking for opportunities in the biotechnology sector.
Company Profile
BioCardia, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO Peter A. Altman. BCDA has traded publicly since 1996.
F-Score 2/9Financial Health
BioCardia, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
A current ratio of 0.41 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -58.0%, the inverse of the P/E and a quick read on earnings relative to price.
BCDA Valuation & Market Position
With a $6.84M market cap, BioCardia, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BCDA's quantitative score of 27/100 is below the peer average of 85/100.
FY2026 estForward Outlook
Wall Street analysts project BioCardia, Inc. revenue of about $50K for fiscal 2026, with EPS near $-0.68.
BCDA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- BioCardia's recent insider buying signals strong confidence from those closest to the company, suggesting they believe the stock is undervalued. The community sentiment is largely positive, with many traders expressing optimism about the company's pipeline and potential market opportunities. There's a growing perception that BioCardia's technology could be a game-changer in its field, attracting attention from larger players. The overall market seems to be warming up to biotech companies with innovative therapies, creating a favorable environment for BCDA.
- The community is buzzing about potential partnerships and collaborations, which could significantly boost BioCardia's visibility and revenue streams. Recent discussions highlight the company's strong intellectual property portfolio as a key asset. Positive clinical trial updates have fueled optimism about the efficacy of BioCardia's treatments. The general consensus is that BioCardia is well-positioned to capitalize on the growing demand for advanced cardiovascular therapies.
Bear Case
- Despite insider buying, some traders are concerned about the company's cash burn rate and potential need for future financing. The community also expresses worries about regulatory hurdles and the lengthy approval process for new therapies. There's a lingering skepticism regarding the commercial viability of BioCardia's products, given the competitive landscape. The market perception is that smaller biotech companies like BioCardia are highly susceptible to volatility and market downturns, similar to what we saw with other small-cap biotechs in early 2022.
- Concerns exist about the company's ability to successfully scale up production and distribution. Some community members are wary of the limited market adoption of similar therapies in the past. Negative sentiment surfaces due to delays in key milestones, creating uncertainty about future growth. The market is cautious about companies with a limited product portfolio, as seen with other single-product biotechs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BCDA Latest News
-
Daily – Vickers Top Insider Picks for 07/02/2026
Argus Research · Jul 2, 2026
-
Daily – Vickers Top Insider Picks for 07/01/2026
Argus Research · Jul 1, 2026
-
Daily – Vickers Top Insider Picks for 06/30/2026
Argus Research · Jun 30, 2026
-
Daily – Vickers Top Insider Picks for 06/29/2026
Argus Research · Jun 29, 2026
BCDA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCDA.
Price Targets
Wall Street price target analysis for BCDA.
BCDA MoonshotScore
What does this score mean?
The MoonshotScore rates BCDA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Leadership: Peter A. Altman
CEO
Peter A. Altman has extensive experience in the biotechnology sector, having held various leadership roles throughout his career. He holds a degree in biology and has a strong background in clinical development and regulatory affairs. His previous roles include senior positions at leading biotech firms, where he successfully guided product development and commercialization strategies.
Track Record: Under Peter A. Altman's leadership, BioCardia has made significant strides in advancing its clinical programs, particularly the CardiAMP Cell Therapy System. His strategic decisions have focused on enhancing clinical trial efficiency and securing partnerships to bolster the company's growth.
BCDA Healthcare Stock FAQ
What does BioCardia, Inc. do?
BioCardia, Inc. is a clinical-stage biotechnology company focused on developing advanced cellular and cell-derived therapies for cardiac and respiratory conditions. The company’s primary product, the CardiAMP Cell Therapy System, aims to treat heart failure and chronic myocardial ischemia, while also exploring allogeneic cell therapies for broader applications. BioCardia is committed to innovative delivery solutions that enhance the efficacy of its therapies.
What are the main risks for BCDA?
BioCardia, Inc. faces several risks inherent to clinical-stage biotechnology companies. Regulatory approval processes can be lengthy and complex, potentially delaying product launches and impacting revenue generation. Additionally, the company may require further financing to support its research and development efforts, which could strain operational capabilities. Finally, competition from established biotechnology firms poses a threat to market share and pricing strategies, making it essential for BioCardia to maintain its competitive edge.
How does BioCardia, Inc. navigate regulatory approval processes?
BioCardia, Inc. navigates regulatory approval processes by adhering to stringent guidelines set forth by the FDA and other regulatory bodies. The company has established a robust compliance strategy that includes thorough documentation, data collection, and clinical trial management to ensure that its products meet safety and efficacy standards. By maintaining open communication with regulatory agencies and leveraging its experienced leadership team, BioCardia aims to streamline the approval process for its innovative therapies.
What are the key factors to evaluate for BCDA?
BioCardia, Inc. (BCDA) holds an AI score of 27/100 (low). Not financial advice.
How frequently does BCDA data refresh on this page?
BCDA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BCDA's recent stock price performance?
BioCardia, Inc. (BCDA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with the CardiAMP Cell Therapy System. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BCDA overvalued or undervalued right now?
Valuing BioCardia, Inc. (BCDA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BCDA?
Before investing in BioCardia, Inc. (BCDA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and is subject to change as new developments occur.